JP Patent

JP6728221B2 — 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Assigned to ヤンセン ファーマシューティカルズ，インコーポレーテッド · Expires 2020-07-22 · 6y expired

What this patent protects

Patent listed against Invega Sustenna.

Drugs covered by this patent

Patent Metadata

Patent number
JP6728221B2
Jurisdiction
JP
Classification
—
Expires
2020-07-22
Drug substance claim
No
Drug product claim
No
Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.